Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) is projected to post its quarterly earnings results after the market closes on Thursday, February 13th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.14) per share and revenue of $52.25 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.
Vanda Pharmaceuticals Price Performance
NASDAQ VNDA opened at $4.72 on Wednesday. The stock has a market capitalization of $275.22 million, a PE ratio of -16.86 and a beta of 0.74. Vanda Pharmaceuticals has a 1-year low of $3.71 and a 1-year high of $6.75. The business has a 50 day simple moving average of $4.63 and a two-hundred day simple moving average of $4.88.
Analyst Ratings Changes
A number of research firms recently weighed in on VNDA. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 4th.
Insider Activity
In other news, Director Stephen Ray Mitchell sold 5,000 shares of the stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 8.90% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
- Five stocks we like better than Vanda Pharmaceuticals
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- Consumer Discretionary Stocks Explained
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
